Sun Pharma Acquires Checkpoint Therapeutics to Expand Oncology Portfolio

Sun Pharmaceutical Industries Limited has announced the acquisition of Checkpoint Therapeutics, a Nasdaq-listed immunotherapy and oncology company, in a strategic move to strengthen its innovative cancer treatment portfolio. The acquisition grants Sun Pharma ownership of UNLOXCYT™ (cosibelimab-ipdl), an FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC). With Sun Pharma’s global reach, the drug is set to become more widely accessible to patients in need of advanced immunotherapy options. Chairman and Managing Director Dilip Shanghvi emphasized the acquisition’s potential to provide a vital new treatment for cSCC patients worldwide.

Checkpoint’s leadership expressed enthusiasm about the partnership, highlighting Sun Pharma’s ability to accelerate access to UNLOXCYT in key markets, including the U.S. and Europe. “Sun Pharma shares our commitment to improving the lives of skin cancer patients,” said Checkpoint CEO James Oliviero. “This acquisition will not only maximize value for our stakeholders but also ensure more patients benefit from our innovative immunotherapy.” With this move, Sun Pharma further cements its position as a leader in onco-dermatology, driving forward its mission to deliver breakthrough treatments to patients across the globe.